Hartford Funds Management Co LLC Has $921,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Hartford Funds Management Co LLC increased its position in Pfizer Inc. (NYSE:PFE) by 5.7% in the third quarter, Holdings Channel.com reports. The firm owned 31,832 shares of the biopharmaceutical company’s stock after acquiring an additional 1,716 shares during the period. Hartford Funds Management Co LLC’s holdings in Pfizer were worth $921,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Pfizer during the first quarter worth $315,000. Bellevue Group AG grew its position in shares of Pfizer by 48.0% during the 1st quarter. Bellevue Group AG now owns 33,834 shares of the biopharmaceutical company’s stock worth $939,000 after buying an additional 10,966 shares during the period. Mount Yale Investment Advisors LLC increased its stake in shares of Pfizer by 25.7% in the 1st quarter. Mount Yale Investment Advisors LLC now owns 22,128 shares of the biopharmaceutical company’s stock valued at $614,000 after acquiring an additional 4,525 shares during the last quarter. Lavaca Capital LLC boosted its stake in Pfizer by 5.6% during the 1st quarter. Lavaca Capital LLC now owns 11,248 shares of the biopharmaceutical company’s stock worth $312,000 after acquiring an additional 601 shares during the last quarter. Finally, Waverly Advisors LLC grew its holdings in Pfizer by 36.3% during the first quarter. Waverly Advisors LLC now owns 165,821 shares of the biopharmaceutical company’s stock valued at $4,602,000 after purchasing an additional 44,118 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on PFE shares. Sanford C. Bernstein began coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. UBS Group increased their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Barclays lifted their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Trading Up 2.1 %

Pfizer stock opened at $25.65 on Friday. The company has a market cap of $145.36 billion, a price-to-earnings ratio of 34.66, a P/E/G ratio of 0.80 and a beta of 0.67. The firm has a 50-day moving average of $28.21 and a 200-day moving average of $28.57. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.17) earnings per share. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.55%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.